NEW YORK, NY--(Marketwire - Mar 11, 2013) - TriMarkPublications.com cites in its newly published "Regenerative Medicine Markets" report that the regenerative medicine market will catapult to over $35 billion by 2019. For more information, visit: http://www.trimarkpublications.com/regenerative-medicine-markets/.
Regenerative medicine (RM) can be categorized into three main modalities: tissue engineering, biomaterials and biomolecules, e.g., scaffolds, growth factors and stem cell therapy. Tissue-engineered bone products in the orthopedic segment will see steady growth, from $7.5 billion in 2012 to $3.29 billion in 2019. The up-and-coming cardiology and vascular products segment will also see substantial growth, reaching a market value of $3.29 over the forecast period.
The "Regenerative Medicine Markets" report covers:
- Tissue-engineered skin, cartilage, bone, peripheral nerves, corneas and blood vessels
- Sell culture products
- Stem cell transplants
- Pluripotent, neural, RPE and limbal stem cells
- Cartilage repair
- Skin ulcers
- Facial reconstruction bone
- Tendon, ligament and blood vessel repair
- Myocardial patches
- Heart valve repair
- Kidney repair
- Bladder repair
- Liver repair
- Bioartificial pancreas
The "Regenerative Medicine Markets" report examines companies manufacturing regenerative medicine equipment and supplies in the world. Companies covered include: Amorcyte, Ars Arthro, Axiogenesis, AxoGen, Bellicum, BetaStem, Bioheart, Biomet, BioMimetic, BioTissue, Biovest, BrainStorm Cell, California Stem Cell, Cardio3, Cellartis, CellSeed, Cellular, Chromocell, Cognate, Cook, Cytomedix, Cytonet, Cytori, DanDrit, Fibrocell, Forticell, Gamida, Harvest, Histogenics, Humacyte, Integra, Intercytex, iPierian, Japan Tissue Engineering, Kensey Nash, Kiadis, Life Cell, Living Cell, MaxCyte, MediStem, Mesoblast, MolMed, NanoCor, Neuralstem, NeuroNova, NewLink Genetics, Olympus Terumo, OncoMed, Opexa, Organogenesis, Orthovita, Osiris, Osteotech, Pervasis, Pluristem, Proneuronnologies, RegeneRx, ReNeuron, Revivicor, SanBio, Saneron, Sangamo, Stem Cell Authority, StemCells, Stemline, Stratetech, Synthecon, Tengion, Thermogenesis, TiGenics, Tissue Genesis, ViaCyte, Vistagen and Zen-Bio.
Detailed charts with sales forecasts and marketshare data are included. For more information, visit: http://www.trimarkpublications.com/regenerative-medicine-markets/.
TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit http://www.trimarkpublications.com.
The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.
- Investment & Company Information
- stem cell therapy